Sartorius Opens New Application Center in Shanghai
Sartorius has officially opened a new application center at its Shanghai office. Among the guests, representatives from the Shanghai government, customers from the biopharmaceutical industry, as well as business partners and the media, attended the opening ceremony.
With a floor space of 240 square meters, or 2600 square feet, the new application center offers ample room for product demonstrations, trial runs and training sessions. At this center, customers from the biopharmaceutical industry can now test the latest Sartorius products for cell cultivation, media and buffer preparation, sterile filtration, cross-flow purification, membrane chromatography, virus clearance and aseptic processing. For laboratory customers, Sartorius showcases its entire range of lab instruments and consumables from balances, moisture analysers, pipettes and water purification systems to filters and products for microbiological testing and quality control.
In his speech, Michael Melingo, member of the Sartorius Group Executive Committee and in charge of marketing, sales and services of Sartorius’ lab business, underlined the importance of Shanghai as a strategic and geographical hub for Sartorius in Asia. “Located close to our customers’ R&D centers in Shanghai and other biotech hotspots like Seoul, Tokyo and Singapore, our application center is the place to be for top scientists to talk about the latest industrial and technological trends.” With the substantial investment in this new application center, Sartorius has further extended its footprint in Asia.
Dr Jörg Lindenblatt, the Senior Vice President of Sales Asia/Pacific for Bioprocess Solutions, emphasised the practical approach of the application center. “Our application center is not just a showroom for our extensive range of lab and bioprocess products. We invite our customers to gain hands-on experience with our
technologies during training and demonstration. By doing this, we can demonstrate the benefits of the high degree of seamless integration of the newest state-of-the-art technology for biotech manufacturing.” Besides being used for demonstration purposes, the new application center will serve as training facility for customers,
distributors and staff.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...